TEVIMBRA provides flexible dosing and scheduling options to pair with your preferred chemotherapy1
TEVIMBRA is administered prior to platinum-based chemotherapy for first-line patients.
For patients with 1L ESCC or 1L GC/GEJC: Follow the dosing schedule that best fits with your preferred platinum-based chemotherapy.
For patients with 2L ESCC: Administer TEVIMBRA as a monotherapy.
The overall management of certain AEs may require treatment interruption or treatment discontinuation, depending on severity
Important reminders
- TEVIMBRA should be inspected visually for particulate matter and discoloration prior to administration
- Do not coadminister other drugs through the same infusion line
- Do not administer TEVIMBRA as an intravenous push or single bolus injection
- The intravenous line must be flushed at the end of the infusion
- TEVIMBRA is for single use only. Discard any unused portion left in the vial
Dosing modification guidance is available to keep your patients at the table
2L, second line; AE, adverse event; ESCC, esophageal squamous cell cancer; GI, gastrointestinal; IV, intravenous.
Reference: 1. TEVIMBRA. Prescribing Information. San Mateo, CA: Beigene, Ltd.; 2025.